Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical leader, focusing on innovative medicines for serious diseases. Headquartered in New York, the company specializes in oncology, immunology, cardiovascular, and fibrosis treatments, combining cutting-edge science with a commitment to patient care and medical innovation.
Key Takeaways:
- BMY’s stock price is projected to show steady growth from 2024 to 2050
- Factors influencing the forecast include market conditions, R&D investments, and industry trends
- Long-term investors may find BMY an attractive option for portfolio growth
- The pharmaceutical sector’s evolution will play a crucial role in BMY’s future valuation
Overview of Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has established itself as a leading player in the pharmaceutical industry. With a focus on developing and delivering innovative medicines, BMY has built a strong portfolio of products across various therapeutic areas.
Founded in 1887, Bristol-Myers Squibb has a storied past marked by significant milestones:
- 1887: The company is established as Bristol-Myers Company
- 1989: Bristol-Myers merges with Squibb Corporation, forming Bristol-Myers Squibb
- 2019: Acquisition of Celgene Corporation, expanding its oncology portfolio
- 2020: Acquisition of MyoKardia, strengthening its cardiovascular franchise
Throughout its history, BMY has demonstrated a commitment to research and development, consistently bringing groundbreaking treatments to market.
Bristol-Myers Squibb Company Profile
| Country | United States |
| Ticker Symbol | BMY |
| Exchange | NYSE |
| Founded | 1887 |
| IPO Date | 1972 |
| Industry | Biopharmaceuticals |
| Sector | Healthcare |
| Employees | 34,100 |
| CEO | Chris Boerner |
| Market Cap (August 9, 2024) | $94.98 billion |
| Website | bms |
Bristol-Myers Squibb Company (BMY) Balance Sheet Analysis
Bristol-Myers Squibb Company (NYSE: BMY) reported total assets of $95.16 billion for the year ending December 31, 2023, a slight decrease from $96.82 billion in 2022. Total liabilities remained stable at $65.67 billion, while total equity declined to $29.49 billion from $31.12 billion in the previous year.
The company’s total debt stood at $41.46 billion, with net debt at $28.31 billion. Working capital improved significantly to $9.51 billion, up from $5.38 billion in 2022. Net tangible assets, although still negative at -$19.22 billion, showed improvement from -$26.44 billion in 2022.
The negative net tangible assets figure indicates substantial intangible assets and goodwill on the balance sheet, which is typical for pharmaceutical companies due to patents and acquired technologies.
Overall, Bristol-Myers Squibb’s 2023 balance sheet reflects a strong financial position, with improved working capital and a slight reduction in total assets and liabilities compared to the previous year, indicating effective management of resources and liabilities.
Balance Sheet Data Source: finance.yahoo
Bristol-Myers Squibb Company Stock Price History
Bristol-Myers Squibb Company (NYSE: BMY) had its IPO in the year 1972. Bristol-Myers Squibb (BMY) had 6 stock splits: 2:1 in 1977, 1983, 1987, 1997, and 1999, plus a 1000000:951777 split in 2001. One pre-1977 share equals 33.62 shares today.1
As of August 8, 2024, the stock price stands at $46.85.
BMY Stock Price Forecast 2024
For the remainder of 2024, we anticipate a modest uptick in BMY’s stock price. Market analysts project a potential growth of 10-12% by year-end, driven by the company’s strong pipeline and ongoing clinical trials. In 2024, BMY is expected to benefit from the continued success of its immunology and hematology portfolios. The company’s focus on oncology breakthroughs and strategic partnerships in emerging markets could drive investor confidence and contribute to stock price appreciation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2024 | $36.85 | $51.54 | $60.91 |
The average price of $51.54 represents a 10% increase from the current price, reflecting cautious optimism in the market.
BMY Stock Price Forecast 2025
As we move into 2025, our forecast becomes more bullish. We expect BMY to benefit from the maturation of its R&D investments and potential new drug approvals. 2025 could see BMY capitalizing on its robust late-stage pipeline. Anticipated approvals in cardiovascular disease treatments and expansion of existing oncology drugs into new indications may drive revenue growth. The company’s digital health initiatives could also start yielding tangible benefits, enhancing operational efficiency.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $51.54 | $58.23 | $69.88 |
The projected average price of $58.23 signifies a 13% year-over-year growth.
BMY Stock Price Forecast 2026
2026 looks promising for BMY shareholders, with continued momentum in the stock price expected. In 2026, BMY’s investments in cell therapy and genomics could start paying off. The company’s efforts in precision medicine and biomarker research may lead to more targeted, effective treatments. Expansion in Asia-Pacific markets might also contribute to revenue growth, positively impacting the stock price.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $58.23 | $66.38 | $82.98 |
Our forecast shows an average price of $66.38, marking a 14% increase from 2025.
BMY Stock Price Forecast 2027
As we approach the latter half of the decade, BMY’s stock is poised for further gains. 2027 might see BMY leveraging its strong position in immuno-oncology to develop next-generation therapies. The company’s continued focus on rare diseases could open up new revenue streams. Strategic collaborations with biotech startups might also enhance BMY’s innovative capabilities, potentially boosting investor confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $66.38 | $75.67 | $94.59 |
The projected average price of $75.67 represents a 14% jump from 2026.
BMY Stock Price Forecast 2028
2028 could be a landmark year for BMY, with our forecast suggesting continued robust growth. By 2028, BMY’s investments in artificial intelligence and machine learning for drug discovery could yield substantial results. The company’s efforts in developing novel biologics and expanding its biosimilars portfolio may contribute to revenue diversification. Increased focus on sustainable practices might also enhance BMY’s appeal to ESG-conscious investors.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $75.67 | $86.27 | $107.84 |
We anticipate an average price of $86.27, reflecting a 14% increase from 2027.
BMY Stock Price Forecast 2029
As we near the end of the decade, BMY’s stock price is expected to maintain its upward trajectory. In 2029, BMY might be at the forefront of personalized medicine, leveraging its vast genomic database and AI capabilities. The company’s potential breakthroughs in neurodegenerative diseases could open up new market opportunities. Strategic acquisitions in emerging biotech fields might also contribute to the company’s growth trajectory.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $86.27 | $98.35 | $127.86 |
The forecast average price of $98.35 indicates a 14% year-over-year growth.
BMY Stock Price Forecast 2030
Entering the new decade, BMY’s stock price is projected to cross into three-digit territory. By 2030, BMY could be a leader in gene therapy and RNA-based treatments. The company’s long-term investments in cutting-edge research areas like nanomedicine might start bearing fruit. Expansion into digital therapeutics and health tech solutions could provide new revenue streams, potentially driving stock price appreciation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $98.35 | $112.12 | $145.76 |
Our forecast points to an average price of $112.12, marking a 14% increase from 2029.
Related: Sumitomo Mitsui Financial Group, Inc. (SMFG) Stock Forecast & Price Prediction
BMY Stock Price Forecast 2031
The upward trend is anticipated to continue into 2031, with BMY’s stock price reaching new heights. In 2031, BMY’s focus on developing treatments for age-related diseases could pay off as global demographics shift. The company’s potential breakthroughs in regenerative medicine might open up new market opportunities. Continued expansion in emerging markets and strategic partnerships in the Asia-Pacific region could drive global growth.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $112.12 | $127.82 | $166.17 |
We project an average price of $127.82, representing a 14% growth from 2030.
BMY Stock Price Forecast 2032
2032 promises to be another strong year for BMY shareholders, with our forecast indicating sustained growth. By 2032, BMY might be leveraging quantum computing for drug discovery, potentially accelerating the development of novel therapies. The company’s investments in sustainable manufacturing practices could enhance its appeal to environmentally conscious investors. Breakthroughs in precision oncology might further solidify BMY’s position as a leader in cancer treatment.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $127.82 | $145.71 | $189.42 |
The projected average price of $145.71 shows a 14% year-over-year increase.
BMY Stock Price Forecast 2033
As we move further into the 2030s, BMY’s stock price is anticipated to maintain its upward momentum. In 2033, BMY’s long-term investments in neurological disorders could yield significant breakthroughs. The company’s potential advancements in immunotherapy might revolutionize cancer treatment. Strategic acquisitions in emerging biotech fields and continued focus on rare diseases could open up new revenue streams, potentially driving stock price appreciation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $145.71 | $166.11 | $215.94 |
Our forecast suggests an average price of $166.11, marking a 14% increase from 2032.
BMY Stock Price Forecast 2034
2034 is expected to be another year of substantial growth for BMY’s stock price. By 2034, BMY might be at the forefront of developing ‘living medicines’ using synthetic biology. The company’s potential breakthroughs in targeting previously ‘undruggable’ proteins could open up new therapeutic possibilities. Expansion into digital health platforms and AI-driven diagnostics might provide additional growth avenues, potentially boosting investor confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $166.11 | $189.37 | $246.18 |
We anticipate an average price of $189.37, representing a 14% jump from 2033.
BMY Stock Price Forecast 2035
As we approach the mid-2030s, BMY’s stock price is projected to continue its ascent. In 2035, BMY could be leading the way in developing treatments for diseases associated with space travel, as commercial space exploration expands. The company’s potential advancements in nanotechnology-based drug delivery systems might revolutionize treatment efficacy. Continued focus on developing countries’ healthcare needs could open up vast new markets.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $189.37 | $215.88 | $280.64 |
The forecast average price of $215.88 indicates a 14% year-over-year growth.
BMY Stock Price Forecast 2036
2036 promises to be another strong year for BMY shareholders, with our forecast suggesting continued robust growth. By 2036, BMY’s investments in epigenetic therapies could start yielding substantial results. The company’s potential breakthroughs in reversing cellular aging might open up entirely new treatment paradigms. Strategic partnerships in quantum biology research could position BMY at the cutting edge of next-generation drug discovery, potentially driving stock price appreciation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $215.88 | $246.10 | $319.93 |
We project an average price of $246.10, marking a 14% increase from 2035.
BMY Stock Price Forecast 2037
As we move into the latter half of the 2030s, BMY’s stock price is expected to maintain its upward trajectory. In 2037, BMY might be leveraging advanced organ-on-a-chip technology for more efficient and ethical drug testing. The company’s potential advancements in targeted protein degradation could revolutionize treatment for previously intractable diseases. Expansion into personalized nutrition and wellness solutions might provide new revenue streams, potentially boosting investor confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $246.10 | $280.55 | $364.72 |
Our forecast points to an average price of $280.55, representing a 14% year-over-year growth.
BMY Stock Price Forecast 2038
2038 is anticipated to be another year of substantial growth for BMY’s stock price. By 2038, BMY could be at the forefront of developing ‘smart’ drugs that can be activated or deactivated on demand. The company’s potential breakthroughs in brain-computer interfaces for treating neurological disorders might open up new therapeutic possibilities. Strategic acquisitions in the field of bioelectronic medicine could provide additional growth avenues.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $280.55 | $319.83 | $415.78 |
We expect an average price of $319.83, marking a 14% increase from 2037.
BMY Stock Price Forecast 2039
As we approach the end of the 2030s, BMY’s stock price is projected to continue its impressive climb. In 2039, BMY might be leading the development of treatments for new diseases emerging from climate change. The company’s potential advancements in 3D-printed personalized medicines could revolutionize drug manufacturing and delivery. Continued focus on developing countries’ healthcare needs and expansion in African markets could open up vast new growth opportunities.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $319.83 | $364.61 | $473.99 |
The forecast average price of $364.61 indicates a 14% year-over-year growth.
BMY Stock Price Forecast 2040
Entering the 2040s, BMY’s stock price is anticipated to reach new heights. By 2040, BMY could be leveraging quantum sensors for ultra-precise drug targeting at the molecular level. The company’s potential breakthroughs in treating cognitive decline and enhancing human memory might open up entirely new market segments. Strategic partnerships in space-based pharmaceutical research could position BMY as a pioneer in extraterrestrial medicine.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $364.61 | $415.66 | $540.36 |
Our projection shows an average price of $415.66, representing a 14% jump from 2039.
BMY Stock Price Forecast 2050
Looking ahead to 2050, our long-term forecast for BMY’s stock price is highly optimistic. In 2050, BMY might be at the forefront of integrating biotechnology with artificial intelligence to create ‘living’ drug factories within the human body. The company’s potential advancements in reversing genetic diseases could revolutionize healthcare. Expansion into terraforming technologies for space colonization might provide unexpected new applications for BMY’s expertise in manipulating biological systems.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $1080.00 | $1200.00 | $1560.00 |
We project an average price of $1200.00, marking a significant increase from 2040.
Conclusion
Our comprehensive analysis of Bristol-Myers Squibb Company’s (NYSE: BMY) stock price forecast from 2024 to 2050 paints a picture of robust and sustained growth. We project the stock price to reach an impressive $1200.00 by 2050, representing a compound annual growth rate (CAGR) of approximately 13.5% over the 26-year period.
This remarkable growth trajectory is underpinned by several factors:
- Continued innovation in drug development
- Strategic acquisitions and partnerships
- Expansion into emerging markets
- Strong performance in key therapeutic areas
- Adaptability to changing healthcare landscapes
FAQs
1. What is the future of BMY share price?
The future of BMY share price appears to be positive, with steady growth projected from 2024 to 2050. The forecast suggests a compound annual growth rate (CAGR) of approximately 13.5% over this period.
2. What is the BMY share prediction for 2030?
According to the forecast, the average share price for BMY in 2030 is predicted to be $112.12, with a low of $98.35 and a high of $145.76.
3. What is the BMY 10 year outlook?
The 10-year outlook for BMY (from 2024 to 2034) is optimistic. The forecast projects growth from an average price of $51.54 in 2024 to $189.37 in 2034, representing significant appreciation over the decade.
4. Is BMY a buy, hold, or sell?
BMY could be considered a “Buy” for long-term investors. The forecast suggests consistent year-over-year growth, indicating potential for long-term value appreciation. BMY’s focus on research and development in key areas like oncology, immunology, and cardiovascular diseases positions it well for future growth.
5. Who are the major competitors of BMY?
Bristol-Myers Squibb (BMS) is a major pharmaceutical company, and its competitors are other large pharmaceutical and biotechnology firms. The key competitors include:
- Pfizer Inc.: A global leader in the pharmaceutical industry, Pfizer competes with BMS in areas like oncology, immunology, and cardiovascular treatments.
- Merck & Co., Inc.: Another pharmaceutical giant, Merck is a major competitor in oncology, particularly with its blockbuster drug Keytruda, which rivals BMS’s Opdivo.
- Johnson & Johnson: Known for its diverse healthcare portfolio, Johnson & Johnson competes with BMS in areas like immunology, oncology, and infectious diseases.
- Roche Holding AG: A Swiss multinational healthcare company, Roche is a strong competitor in oncology and immunology with its extensive range of cancer therapies.
- AbbVie Inc.: Specializing in immunology and oncology, AbbVie competes directly with BMS, especially in the field of autoimmune diseases and cancer treatments.
- AstraZeneca PLC: A major player in oncology, cardiovascular, and respiratory diseases, AstraZeneca competes with BMS in multiple therapeutic areas.
- Novartis AG: A global healthcare company based in Switzerland, Novartis competes with BMS in oncology, cardiology, and immunology.
These companies, like BMS, invest heavily in research and development to bring new drugs to market, often competing directly in similar therapeutic areas.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
Source:
